The FDA has granted a fast review for Horizon Therapeutics’ teprotumumab for active thyroid eye disease (TED), a rare vision-threatening autoimmune condition.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS